Reducing Medicare Advantage Benchmarks Will Decrease Plan Generosity, But Those Effects Will Likely Be Modest.


Journal

Health affairs (Project Hope)
ISSN: 1544-5208
Titre abrégé: Health Aff (Millwood)
Pays: United States
ID NLM: 8303128

Informations de publication

Date de publication:
04 2023
Historique:
medline: 5 4 2023
pubmed: 23 3 2023
entrez: 22 3 2023
Statut: ppublish

Résumé

Concerns that Medicare Advantage (MA) plans are overpaid have motivated calls to reduce MA benchmarks-the dollar amounts set by the Centers for Medicare and Medicaid Services (CMS) against which MA plans bid to set premiums and fund extra benefits. However, cutting benchmarks may lead to higher MA enrollee premiums and decreased plan generosity. We assessed the relationships between MA benchmarks and plan generosity and benefits. We estimated that a $1,000 per year decrease in benchmarks would lead to small increases in annual premiums of about $60 and increases in annual deductibles of about $27. Copays would also increase modestly, and the propensity to offer benefits would generally decline by less than 5 percentage points, with the greatest impact being on the availability of dental, hearing, and vision benefits. These results suggest that although cuts to MA benchmarks would adversely affect plan generosity, those effects would be modest.

Identifiants

pubmed: 36947715
doi: 10.1377/hlthaff.2022.01031
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-487

Auteurs

Michael E Chernew (ME)

Michael E. Chernew (Chernew@hcp.med.harvard.edu), Harvard University, Boston, Massachusetts.

Keaton Miller (K)

Keaton Miller, University of Oregon, Eugene, Oregon.

Amil Petrin (A)

Amil Petrin, University of Minnesota, Minneapolis, Minnesota.

Robert J Town (RJ)

Robert J. Town, University of Texas at Austin, Austin, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH